It is looking increasingly as if the Covid-19 pandemic will be remembered for the global politics of the vaccine. It started with so much promise — a worldwide collaboration of universities, governments and industry to produce a vaccine in rapid time; and an international regime, Covax, to ensure its equitable distribution across the world.

But already the goal of equitable distribution is a slipping away; most of the projected stock of vaccine to be manufactured in the next year has been bought by high- and upper-middle-income countries. The consequences will be horribly dystopian...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now